Melanoma antigen recognized by T-cells 1 Terminated Phase 2 Trials for Melanoma (Skin) Stage IV / Recurrent Melanoma Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01307618Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma